FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
nstruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Clancy Paul J						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]									applio Directo	cable)	g Pers	son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) BIOGEN IDEC INC. 225 BINNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 02/08/2015									below) Executive VI			below)	
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)					_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deriv	ative	Se	curit	ies Ac	quired	Dis	sposed o	of, or Be	neficia	lly Ov	vned	l			
1. Title of Security (Instr. 3) 2. Trans: Date (Month/I						ur) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			i. Amount of Securities Beneficially Dwned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
										v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3		tion(s)			(Instr. 4)
Common Stock 02/08/					/2015	2015			M		3,191	A	\$0		18,646			D	
Common Stock 02/0					3/2015				F		1,143	D	\$40	2	17,503			D	
Common Stock 02/09/					2015				M		4,691	A	\$0	22,194		,194	D		
Common Stock 02/09/2					/2015	2015					2,210	D	\$396.	88	8 19,984			D	
		Т	able II -								osed of			y Owr	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,		Transaction Code (Instr.		n of		6. Date Exercisa Expiration Date (Month/Day/Yea		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Prio Derivo Secui (Instr.	ative ity	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	\$0	02/08/2015			M			3,191	(1)		02/08/2016	Common Stock	3,191	\$		3,194		D	
Restricted	\$0 ⁽²⁾	02/09/2015			M			4,691	(1)		02/09/2015	Common	4,691	\$)	0		D	

Explanation of Responses:

Stock Unit

/s/ Matthew S. Gilman,

02/10/2015 Attorney in Fact for Paul

Clancy

Stock

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

^{2.} There is no conversion or exercise price for this stock unit.